FDA slaps hold on Celyad phase 1 colorectal cancer trial

 

• The FDA has issued a clinical hold on Celyad Oncology SA's 
  CYAD -0.88%
   (Get Free Alerts for CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects.
• As previously disclosed, the Company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.
• Celyad Oncology is a clinical-stage biotechnology company focused on discovering and developing chimeric antigen receptor T cell (CAR T) therapies for cancer. 
• The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for hematological malignancies and solid tumors.

https://www.benzinga.com/general/biotech/22/03/25932756/fda-slaps-clinical-hold-on-celyads-phase-1-colorectal-cancer-trial